ISPOR 19TH ANNUAL EUROPEAN CONGRESS ISSUE PANEL EXPLORES ISSUE OF ADAPTIVE PATHWAYS AND PATIENT ACCESS

Published Nov 1, 2016
Vienna, Austria—1 November 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) held an issue panel this afternoon entitled, Adaptive Pathways and Patient Access: Pushing Payer Boundaries or Facilitating New Payment Models? The session took place at the Society’s 19th Annual European Congress in Vienna, Austria.  The issue panel was moderated by Jacoline Bouvy, PhD, Scientific Adviser, National Institute for Health and Care Excellence, London, UK. Speakers for the session included:
  • Hans-Georg Eichler, MD, MSc, Senior Medical Officer, European Medicine Agency, London, UK
  • Ad Schuurman, MSc, MBA, President of MEDEV, Zorginstituut Nederland, Diemen, The Netherlands
  • Claudine Sapede, PharmD, MSc, Global HTA and Payment Policy Lead, F. Hoffmann-La Roche Ltd, Basel, Switzerland
This panel explored the use of adaptive pathways in the development medicines. Speakers noted that adaptive pathways could help patients gain earlier access to promising treatments in areas of high unmet medical needs, but acknowledged that this approach may also have implications for access decisions at the national and regional levels that need to be explored. Jacoline Bouvy, PhD provided an overview of ADAPT SMART, the enabling platform for the coordination of Medicines Adaptive Pathways for Patients (MAPPs) activities. MAPPS seeks to foster access to beneficial treatments for the right patient groups at the earliest appropriate time in the product lifespan in a sustainable fashion. Hans-Georg Eichler, MD, MSc discussed the regulatory viewpoint on adaptive pathways, and Ad Schuurman, MSc, MBA and Claudine Sapede, PharmD, MSc provided perspectives from the payer and industry sectors, respectively. Additional information on the ISPOR 19th Annual European Congress can be found here. Released presentations from the congress can be found here. Interested parties can follow news and developments from the conference on social media using the hashtag #ISPORVienna.

###

Related Stories

ISPOR Task Force Addresses Critical Gap in Surrogate Endpoint Guidance

May 28, 2026

Value in Health, announced the publication of an ISPOR Good Practices Report providing guidance on the use of surrogate endpoint evaluation methods in health technology assessment (HTA) decision making. The report, “Methods for Evaluation of Surrogate Endpoints for HTA Decision Making: A Good Practices Report of an ISPOR Task Force,” was published in the May 2026 issue of Value in Health.

How Is Health Valued in the United Kingdom? We Finally Have a Better Answer

May 27, 2026

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a pair of companion articles that together establish both the methodological foundation of the first definitive UK value set for the EQ-5D-5L and the practical implications of adopting it—thus equipping health technology assessment decision makers with a UK value set suitable for informing policy. The articles were featured in the May 2026 issue of Value in Health.

ISPOR Announces 2026-2027 Board of Directors

May 26, 2026

ISPOR—The Professional Society for Health Economics and Outcomes Research announced its 2026-2027 board of directors who will assume office on July 1, 2026.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×